P59.9 is a billable diagnosis code used to specify a medical diagnosis of neonatal jaundice, unspecified. The code P59.9 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
JAUNDICE NEONATAL-. yellow discoloration of the skin; mucous membrane; and sclera in the newborn. it is a sign of neonatal hyperbilirubinemia. most cases are transient self limiting physiological neonatal jaundice occurring in the first week of life but some can be a sign of pathological disorders particularly liver diseases.
FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)
There are 4 categories of codes for newborn jaundice as per the cause – P55 (hemolytic disease), P57 (kernicterus), P58 (due to other hemolytic reasons) and P59 (Neonatal jaundice from other specified causes)
Note: Obstructive jaundice should be coded to obstruction of bile duct K83.1
This is more than the liver capacity. Causes of prehepatic jaundice are thalassemia, sickle cell anemia, autoimmune disease and transfusion
Common symptoms of jaundice are yellow skin and white of eyes, dark coloured body fluids ( urine and stool). If jaundice along with severe abdominal pain, blood vomit, blood in stool, change in mental function, fever or tendency to bleed easily are cause of concern.
Obstructive jaundice or regurgitation jaundice guide us to see obstruction bile duct which leads to K83.1
Note: Hyperbilirubinemia in new born should be coded as jaundice new born as per ICD-10 CM manual index list.
Aetna considers the use of metalloporphyrins (e.g., stannsopor fin (tin mesoporphyrin), Stanate, WellSpring Pharmaceutical Corporation, Neptune, NJ) for the treatment of neonatal jaundice experimental and investigational because their safety and effectiveness for this indication has not been established.
TSB is less than 20 to 22 mg/dL in term infants, or less than 18 mg/dL in preterm infants; and
Aetna considers home phototherapy for physiologic jaundice in healthy infants with a gestational age of 35 weeks or more medically necessary if all of the following criteria are met:
Aetna considers transcutaneous bilirubin devices for evaluating hyperbilirubinemia in term and near-term infants while undergoing phototherapy experimental and investigational becasue this approach is not reliable in infants in this setting.
According to available guidelines, no further measurement of bilirubin is necessary in most cases.
Chen and co-workers (2017) stated that probiotics supplementation therapy could assist to improve the recovery of neonatal jaundice, through enhancing immunity mainly by regulating bacterial colonies. However, there is limited evidence regarding the effect of probiotics on bilirubin level in neonates. These researchers systematically evaluated the safety and efficacy of probiotics supplement therapy for pathological neonatal jaundice. Databases including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang Database (Wan Fang), Chinese Biomedical Literature Database (CBM), VIP Database for Chinese Technical Periodicals (VIP) were searched and the deadline was December 2016; RCTs of probiotics supplementation for pathological neonatal jaundice in publications were extracted by 2 reviewers. The Cochrane tool was applied to assessing the risk of bias of the trials. The extracted information of RCTs should include efficacy rate, serum total bilirubin level, time of jaundice fading, duration of phototherapy, duration of hospitalization, adverse reactions. The main outcomes of the trials were analyzed by Review Manager 5.3 software. The RR or MD with a 95 % CI was used to measure the effect. A total of 13 RCTs involving 1,067 neonatal with jaundice were included in the meta-analysis. Probiotics supplementation treatment showed efficacy [RR: 1.19, 95 % CI: 1.12 to 1.26), p < 0.00001] in neonatal jaundice. It not only decreased the total serum bilirubin level after 3 days [MD: -18.05, 95 % CI: -25.51 to -10.58), p < 0.00001], 5 days [MD: -23.49, 95 % CI: -32.80 to -14.18), p < 0.00001], 7 days [MD: -33.01, 95 % CI: -37.31 to -28.70), p < 0.00001] treatment, but also decreased time of jaundice fading [MD: -1.91, 95 % CI: -2.06 to -1.75), p < 0.00001], as well as the duration of phototherapy [MD: -0.64, 95 % CI: -0.84 to -0.44), p < 0.00001] and hospitalization [MD: -2.68, 95 % CI: -3.18 to -2.17), p < 0.00001], when compared with the control group. Additionally, no serious adverse reaction was reported. The authors concluded that this meta-analysis showed that probiotics supplementation therapy was an effective and safe treatment for pathological neonatal jaundice. Moreover, they stated that as the quality of included studies and the limitations of samples, the long-term safety and efficacy still need to be confirmed by long-term and high-quality research.
Notes: Prophylactic phototherapy is considered medically necessary for infants showing a rapid rise in bilirubin (greater than 1 mg/dL/hour) and as a temporary measure when one is contemplating exchange transfusion. Clofibrate in combination with phototherapy for neonatal hyper bilirubinemia is considered experimental and investigational.
The ICD code P59 is used to code Neonatal jaundice. Neonatal jaundice or Neonatal hyperbilirubinemia, or Neonatal icterus (from the Greek word ἴκτερος), attributive adjective: icteric, is a yellowing of the skin and other tissues of a newborn infant.
In newborns, jaundice is detected by blanching the skin with pressure applied by a finger so that it reveals underlying skin and subcutaneous tissue. Jaundiced newborns have yellow discoloration of the white part of the eye, and yellowing of the face, extending down onto the chest. Specialty: Pediatrics. MeSH Code: D007567.
Billable codes are sufficient justification for admission to an acute care hospital when used a principal diagnosis.
R17 is a billable diagnosis code used to specify a medical diagnosis of unspecified jaundice. The code R17 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.#N#The ICD-10-CM code R17 might also be used to specify conditions or terms like acute cholestatic jaundice syndrome, cholestatic jaundice syndrome, chronic cholestatic jaundice syndrome, conjugated hyperbilirubinemia, elevated total bilirubin , finding of color of limb, etc.#N#Unspecified diagnosis codes like R17 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.
JAUNDICE NEONATAL-. yellow discoloration of the skin; mucous membrane; and sclera in the newborn. it is a sign of neonatal hyperbilirubinemia. most cases are transient self limiting physiological neonatal jaundice occurring in the first week of life but some can be a sign of pathological disorders particularly liver diseases.
JAUNDICE OBSTRUCTIVE -. jaundice the condition with yellowish staining of the skin and mucous membranes that is due to impaired bile flow in the biliary tract such as intrahepatic cholestasis or extrahepatic cholestasis.
The ICD code P59 is used to code Neonatal jaundice. Neonatal jaundice or Neonatal hyperbilirubinemia, or Neonatal icterus (from the Greek word ἴκτερος), attributive adjective: icteric, is a yellowing of the skin and other tissues of a newborn infant. A bilirubin level of more than 85 μmol/l ...
In newborns, jaundice is detected by blanching the skin with pressure applied by a finger so that it reveals underlying skin and subcutaneous tissue. Jaundiced newborns have yellow discoloration of the white part of the eye, and yellowing of the face, extending down onto the chest. Specialty: Pediatrics. MeSH Code:
P59. Non-Billable means the code is not sufficient justification for admission to an acute care hospital when used a principal diagnosis. Use a child code to capture more detail. ICD Code P59 is a non-billable code.
Neonatal jaundice occurs in about two thirds of all newborns.(1) The vast majority of jaundiced newborns have elevated unconjugated bilirubin levels, most often due to hemolytic causes.
An undetectable amount of CB is the norm and anything above 0.3 mg/dL is 2 standard deviations above the mean. Because of the differences in how these two measurements are made, DB levels were considerably higher than CB levels, but even with DB levels 98.6% of measurements were 2 mg/dL or less.
779.3 Nonspecific abnormal findings on examination of biliary tract